Using 68Ga-DOTATOC PET to evaluate gastroenteropancreatic neuroendocrine tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients diagnosed with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and aims to incorporate 68Ga-DOTATOC PET/CT scans into their diagnostic work-up. The study will assess the effectiveness of this imaging technique, which targets somatostatin receptors commonly found on these tumors, providing high sensitivity and specificity. Patients over 18 years old with a confirmed diagnosis of GEP-NET will be included, while those with contraindications to MRI will be excluded. The goal is to enhance the diagnostic process for GEP-NETs and improve patient management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with either histological diagnosis of GEP-NET at radiologic imaging and referred to 68Ga-DOTATOC PET;
* Age \> 18 years old;
* Willing to provide a signed informed consent.

Exclusion Criteria:

* Controindications to MR study (i.e. Pacemaker);
* Age\< 18 years old.

Where it's running

• Irccs San Raffaele
  Milan, Italy Recruiting

Study contacts

• Study coordinator: Arturo Chiti
• Email: chiti.arturo@hsr.it
• Phone: 0226432716

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• GEP-NET treatment patterns and outcomes in the U.S.

  This study will see how newly diagnosed GEP-NET patients are treated in real-world settings and what their outcomes look like.

  Recruiting Novartis · East Hanover, New Jersey · NCT07635316

• Nutritional status monitoring for adults with gastroenteropancreatic neuroendocrine tumors

  This project will see if nutrition problems are common and linked to outcomes in adults aged 18–70 being followed for gastroenteropancreatic neuroendocrine tumors at Strasbourg University Hospital.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07302100

• RYZ401 for solid tumors that express somatostatin receptors

  This trial will try RYZ401, a targeted radiotherapy, in adults with neuroendocrine or other solid tumors that show somatostatin receptors to find a safe dose and see if it shrinks tumors.

  Recruiting at 15 sites Phase 1 RayzeBio, Inc. · Phoenix, Arizona and 14 other locations · NCT07165132

• Characterizing Gastroenteropancreatic Neuroendocrine Tumors Treated With Targeted Radionuclide Therapy

  This study is trying to see if advanced imaging can help doctors choose the right patients for a specific cancer treatment for gastroenteropancreatic neuroendocrine tumors to improve their chances of success.

  Recruiting at 3 sites Assistance Publique - Hôpitaux de Paris · Clichy and 4 other locations · NCT06256705

• Continuing somatostatin analogues for patients with advanced neuroendocrine tumors

  This study is testing whether continuing somatostatin therapy helps people with advanced neuroendocrine tumors do better after their initial treatment compared to stopping the therapy when they start a new treatment.

  Recruiting at 9 sites Phase 4 University Hospital, Antwerp · Brasschaat, Antwerp and 18 other locations · NCT05701241

• Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

  This study is testing a new type of treatment using targeted alpha-particle therapy to see if it can help people with advanced neuroendocrine tumors that have a specific protein called SSTR2.

  Recruiting at 20 sites Phase 1/2 Perspective Therapeutics · Jacksonville, Florida and 19 other locations · NCT05636618

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.